Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · April 01, 2023

Anti-GD2 Antibody Dinutuximab Beta and Low-Dose IL-2 After Haplo-SCT for Relapsed Neuroblastoma

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial
J. Clin. Oncol 2023 Feb 28;[EPub Ahead of Print], T Flaadt, RL Ladenstein, M Ebinger, HN Lode, HB Arnardóttir, U Poetschger, W Schwinger, R Meisel, FR Schuster, M Döring, PF Ambros, M Queudeville, J Fuchs, SW Warmann, J Schäfer, C Seitz, P Schlegel, IB Brecht, U Holzer, T Feuchtinger, T Simon, JH Schulte, A Eggert, HM Teltschik, T Illhardt, R Handgretinger, P Lang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Brain Cancer Center of Excellence

Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.

Further Reading